Biotechnology company MedImmune said Tuesday it has expanded a bioresearch collaboration it started with the University of System of Maryland.
The Gaithersburg company, a development arm of AstraZeneca, started the partnership with the University of Maryland Baltimore in 2013 and will now also work with campuses in College Park and Baltimore County.
Research will start on five projects under the expanded agreement. MedImmune will contribute at least $5 million to the partnership over a five-year period, and the University System of Maryland institutions will contribute $800,000. The state Department of Business and Economic Development is contributing $200,000 in the first year. Future financial support will be based on available funding.
Twitter.com/ankwalkerCopyright © 2014, The Baltimore Sun